Regencell Bioscience Holdings Limited (RGC) vs Supernus Pharmaceuticals, Inc. (SUPN)

Regencell Bioscience Holdings Limited and Supernus Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Regencell Bioscience Holdings Limited is the larger, with a market value of $3.1B against $2.5B — 1.2× the size. Regencell Bioscience Holdings Limited has the higher net margin (0.00% vs −13.2%) and the higher return on invested capital (0.00% vs −12.4%). Across the 10 metrics below, Regencell Bioscience Holdings Limited leads on 5 and Supernus Pharmaceuticals, Inc. on 5.

Valuation

Metric RGC SUPN Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S n/m 2.98 2.25
P/B n/m 2.40 1.90
Price to free cash flow n/m 147.92 16.54
EV/EBITDA 0.19 n/m 12.29
EV/Sales n/m 2.59 2.56
Earnings yield (16.69%) (4.50%) (2.99%)
Free cash flow yield 0.00% 0.68% 0.00%

Profitability

Metric RGC SUPN Drug Manufacturers Specialty & Generic median
Gross margin — 88.07% 53.94%
Operating margin — (15.71%) 0.00%
Net margin 0.00% (13.23%) 0.00%
Free cash flow margin 0.00% 2.21% 0.00%
Return on equity 0.00% (10.49%) (0.40%)
Return on assets 0.00% (7.82%) (3.32%)
Return on invested capital 0.00% (12.37%) 0.00%

Growth

Metric RGC SUPN Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 24.85% 10.01%
EPS growth (last fiscal year) 17.24% (151.52%) —
Revenue growth, 5-year CAGR — 6.68% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RGC SUPN Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.05
Current ratio 1.42 2.08 2.31
Net debt to EBITDA 1.33 (11.12) 0.85

Dividend

Metric RGC SUPN Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric RGC SUPN Drug Manufacturers Specialty & Generic median
Market cap 3.06b 2.52b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack